Anti-ErbB3 / HER3 antibody (ab34641)
Key features and details
- Rabbit polyclonal to ErbB3 / HER3
- Suitable for: IP
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-ErbB3 / HER3 antibody
See all ErbB3 / HER3 primary antibodies -
Description
Rabbit polyclonal to ErbB3 / HER3 -
Host species
Rabbit -
Tested Applications & Species
Application Species IP Human -
Immunogen
Fusion protein corresponding to Human ErbB3/ HER3 aa 1283-1323. ErbB3/ HER3 fusion protein: PASEQGYE E MRAFQGPGH QAPHVHYARL KTLRSLEAT D SAF, corresponding to C terminal amino acids 1283-1323 of Human ErbB3/ HER3
Sequence:PASEQGYE E MRAFQGPGH QAPHVHYARL KTLRSLEAT D SAF
-
Positive control
- IP: LNCap prostate cell line treated with Heregulin-beta1.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 0.42% Potassium phosphate, 0.87% Sodium chloride -
Concentration information loading...
-
Purity
Protein A purified -
Purification notes
This product is an IgG fraction antibody purified from monospecific antiserum by Protein A chromatography followed by cross adsorption against GST and extensive dialysis against the storage buffer. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab34641 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
IP |
Human
|
Application | Abreviews | Notes |
---|---|---|
IP |
Use at an assay dependent concentration.
Use 5µg. The immunoprecipitation mix contained the antibody, 25 µl of Protein A-agarose beads and 1.0 ml of lysate (lysate contains approximately 1.0 mg of total protein). |
Notes |
---|
IP
Use at an assay dependent concentration. Use 5µg. The immunoprecipitation mix contained the antibody, 25 µl of Protein A-agarose beads and 1.0 ml of lysate (lysate contains approximately 1.0 mg of total protein). |
Target
-
Function
Binds and is activated by neuregulins and NTAK. -
Tissue specificity
Epithelial tissues and brain. -
Involvement in disease
Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:607598]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain. -
Developmental stage
Overexpressed in a subset of human mammary tumors. -
Domain
The cytoplasmic part of the receptor may interact with the SH2 or SH3 domains of many signal-transducing proteins. -
Post-translational
modificationsLigand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. -
Cellular localization
Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 2065 Human
- Omim: 190151 Human
- SwissProt: P21860 Human
- Unigene: 118681 Human
-
Alternative names
- c erbB 3 antibody
- c erbB3 antibody
- Erb b2 receptor tyrosine kinase 3 antibody
see all
Images
-
All lanes : Anti-ErbB3 / HER3 antibody (ab34641) (used at 5ul for immunoprecipitation followed by immunoblot detection using an anti-phosphotyrosine antibody)
Lane 1 : LNCap prostate cell line no treatment
Lane 2 : LNCap prostate cell line treated with Heregulin beta1 for 15mins at 100ng/ml
Developed using the ECL technique.
Observed band size: 180 kDa why is the actual band size different from the predicted?
Exposure time: 1 minute
Protocols
Datasheets and documents
References (2)
ab34641 has been referenced in 2 publications.
- Poitelon Y et al. Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral myelination. Nat Commun 6:8303 (2015). WB ; Rat . PubMed: 26383514
- Yan X et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer 13:220 (2014). WB ; Human . PubMed: 25248370